EOLS Evolus Inc

Evolus to Participate in Barclays 2020 Global Healthcare Conference

Evolus to Participate in Barclays 2020 Global Healthcare Conference

NEWPORT BEACH, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that management will be participating in the Barclays 2020 Global Healthcare Conference in Miami, Florida.

     
  Event: Barclays 2020 Global Healthcare Conference
  Format: Fireside chat & 1x1 Meetings
  Date: Wednesday, March 11, 2020
  Time: 3:20 – 3:45pm ET
  Location: Loews Miami Beach Hotel, Miami Beach, Florida
     

An audio webcast of Evolus’ presentation will be available on the investor relations section of Evolus’ website at investors.evolus.com. Replays of the webcasts will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure technology. Jeuveau® is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: .

Jeuveau® is a registered trademark of Evolus, Inc.

Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investor Contact:

Ashwin Agarwal, Evolus, Inc.

Vice President, Finance, Investor Relations & Treasury

Tel:

Email:

Media Contact:

Crystal Muilenburg, Evolus, Inc.

Vice President, Corporate Communications & Public Relations

Tel:

Email:

EN
03/03/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Evolus Inc

Evolus Inc: 2 directors

Two Directors at Evolus Inc sold/sold after exercising options 478,932 shares at between 12.728USD and 12.960USD. The significance rating of the trade was 74/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 10, 2022

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch